Our results showed that vemurafenib induces exit from the cell cycle concurrent to shifting BRAF-positive melanoma cells from proliferative to senescent state that was evaluated by histochemical assay detecting the β-galactosidase activity and the altered expression levels of cell cycle-related proteins — CCND1 and RBL1. Here, BRAF is linked to melanoma.